InSight Biopharmaceutical
Biosimilar and Generic Drug Development
Company Overview
Snapshot
Founded in June 1995 by Naim Tamari, InSight Biopharmaceutical operates with 11–50 employees. The company was acquired by Gencor Pacific in January 2019.
Business overview
InSight Biopharmaceutical specializes in the development of biosimilar drugs, creating products with properties virtually identical to existing approved medications. The company focuses on introducing these biosimilars to major markets through strategic alliances, serving the health tech and life sciences sectors. Its portfolio spans biosimilars in fertility, oncology, neurology, and rheumatology, with products including Trastuzumab, Etanercept, and Rituximab.
Strategic signal
In January 2019, InSight Biopharmaceutical was acquired by Hong Kong's Gencor Pacific. This acquisition marks a significant strategic shift for InSight, indicating a consolidation within the biosimilar drug development market and providing Gencor Pacific with an expanded portfolio in fertility, oncology, neurology, and rheumatology.
Log in to access full profile ›Company Intelligence Q&A
- When was InSight Biopharmaceutical founded?
- InSight Biopharmaceutical was founded in June 1995.
- Who founded InSight Biopharmaceutical?
- Naim Tamari co-founded InSight Biopharmaceutical.
- What was a key acquisition event for InSight Biopharmaceutical?
- In January 2019, InSight Biopharmaceutical was acquired by Gencor Pacific, a Hong Kong-based company, as reported by Calcalistech.
- What was another significant acquisition involving InSight Biopharmaceutical?
- In July 2017, InSight Biopharmaceutical was acquired by PharmaEstica Manufacturing.
- What was a notable event regarding InSight Biopharmaceutical's acquisition activities?
- In July 2018, InSight Biopharmaceutical pulled out of a previously announced acquisition of CureTech.